Mochida Pharmaceutical Co., Ltd.

Merck Sharp + Dohme Corp.

Hidemitsu Nishida

Fumihiko Saitoh

Masayuki Ohashi

Toshiyuki Shudo

William J Greenlee

Samuel Chackalamannil

Michael P Dwyer

Yan Xia

Akira Kikuchi

Tin-Yau Chan

Mariappan Chelliah

Martin C Clasby

Tomokazu Hirabayashi

Takafumi Mukaihira

Kazumi Nishijima

Kazutoshi Yanagibashi

Ikuya Shiromizu

Kousuke Harada

Santhosh Francis Neelamkavil

Unmesh G Shah

Tatsuto Notsu

Tatsuto Notso

Mariappan V Chelliah

The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

Morpholinone compounds as factor IXA inhibitors

Morpholinone compounds as factor IXa inhibitors

This invention relates to tricyclic compounds having spiro union represented by the following formula (I) or its salt which is useful as a drug, and in particular, as an inhibitor for activated blood coagulation factor X, which can be administered orally and which exhibits strong anticoagulation action.  The invention also relates to a pharmacophore which was derived from the compound and is useful in molecular designing of the FXa inhibitor.

Tricyclic compound having spiro union

This invention relates to tricyclic compounds having spiro union represented by the following formula (I) or its salt which is useful as a drug, and in particular, as an inhibitor for activated blood coagulation factor X, which can be administered orally and which exhibits strong anticoagulation action. The invention also relates to a pharmacophore which was derived from the compound and is useful in molecular designing of the FXa inhibitor.

Novel fused tetracyclic heterocyclic compounds having a potent and highly selective effect of inhibiting cyclic GMP phosphodiesterase (cGMP-PDE) and a high safety; a process for producing the same; drugs characterized by containing at least one of these compounds as the active ingredient, in particular, preventives and/or remedies for pulmonary hypertension, ischemic heart diseases, erectile insufficiency, female sexual dysfunction or diseases against which cGMP-PDE inhibitory effects are efficacious and intermediates useful in producing the above compounds.

Compounds having cGMP-PDE inhibitory effect

The invention relates to novel pyridocarbazole derivatives having highly selective action in inhibiting cyclic GMP-phosphodiesterase (hereinafter abbreviated as cGMP-PDE), processes for producing such derivatives, agents containing at least one of such derivatives as an active ingredient for preventing and/or treating pulmonary hypertension, ischemic heart diseases or diseases against which the cGMP-PDE inhibitory action is effective, and intermediates useful for the production of pyridocarbazole derivatives.

Pyridocarbazole derivatives having cgmp-pde inhibitory activity

Pyridocarbazole derivatives having cGMP-PDE inhibitory activity

Growing community of inventors

Tokyo, Japan

Hidemitsu Nishida